Exxel Pharma to Participate in a "New to Virtual Investor" Segment
-
Thukukile Zuma Resigns from ANC Johannesburg Leadership Amid Disciplinary Dispute
-
Russia Orders 100,000 Kometa Modules to Counter Ukrainian Electronic Warfare
-
CM Mohan Yadav Meets Bohra Spiritual Leader to Discuss Simhastha 2028 and Development
-
Mahayuti-backed Rajesh Patil Elected Chairman of Gokul Dairy Amidst Political Deadlock
-
Eli Crane Defeats Jonathan Nez in Tight Arizona Congressional Race
-
David Walliams Identified as Celebrity in Sexual Misconduct Allegations After Legal Bid
-
Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
-
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
NextBoat Inc. to Announce Third Quarter 2026 Financial and Operating Results on Monday, November 16, 2026
-
Shooting Victim Lawyer in Philadelphia David P. Thiruselvam Explains When Property Owners and Businesses Can Face Civil Claims After a Shooting
-
Retired Army Officer Earns Two Degrees While Navigating Family Health Challenges
-
Remergify Opens Waitlist for AI Allowance, a Plain-English Way to Let AI Assistants Shop Within Limits You Set
-
An Investigational Drug to Tackle Measles Outbreaks
-
Ondas Receives Purchase Order for Next-Generation Tactical Attack Drones, Aims to Leverage Planned ARAN Defense Acquisition to Manufacture Thousands of Systems
-
First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
-
Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
-
ACCESS Newswire Reports Third Quarter 2026 Results
-
T4 Robotics Appoints Paul Hughes as Co-CEO and Announces Expansion into Unmanned Maritime Systems
-
ClearSign Receives Order for "M1" Series Burner from Tulsa Heaters Midstream (THM)
-
Kalm with Kava and Pū'iwa Farms Hawai'i Bring Fresh Frozen Hawaiian Kava to Market
-
Innovative Menopause Medicine from JASTLabs Advances Patent Protection Internationally
-
SMX Advances Development of its Scientific Intelligence, an AI-Powered Platform Intended to Create a Comprehensive Codex for Chemical Agents, Additives and Supplements
-
Jerash Holdings Reports Fiscal 2027 Second Quarter Financial Results
-
Four Nines Gold Intersects 67 Metres at 1.78 g/t Gold, Reinforing Emerging Gold Corridor at Hayden Hill
-
Peraso to Showcase DUNE 60 GHz Wireless Platform at Africa Tech Festival 2026
-
Your Patients Are Asking AI About You. AimwellBio Lets Every Physician See the Answer, Free.
-
ByNext Joins the Bilt Neighborhood: Reaching More Customers by Integrating Its Technology with Bilt Neighborhood OS
-
ATWEC Technologies, Inc. (OTCID:ATWT) Reports Third Quarter 2026 Revenue of $12.46 Million, Up 37% Year-over-Year
-
Cardiff Lexington To Report Third Quarter 2026 Financial Results and Host Conference Call on Monday, November 16, 2026
-
Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
-
Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations
-
BioTech Breakthrough Acknowledges Champions Oncology Innovation with the "Contract Research and Development Innovation Award"
-
Allstar Health Brands Confirms MLS NEXT Expansion Bid to Anchor a Permanent Training Structure and a Professional Pathway
-
SNZweig Forms AEC Industry Advisory Council
-
Critical Elements' 10,000-Meter Summer Drill Program at Rose West Continues to Deliver Positive Results
-
New Gold IRA Investing Guide Explains How to Buy Gold in an IRA for American Consumers
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10
-
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist
-
Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges
-
3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
-
Apex Extends Trinity Zone in West Step-out Drilling With 2.52% REO Over 223.3 m and 2.49% REO Over 123.3 m at Rift
-
KIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences Review
-
Zomedica Announces "Third Friday at Four" Webinar on November 20, 2026: The People Behind Zomedica - Seven Guiding Principles in Action, and Q3 Financial Results
-
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
-
Geek+ Unveils 24/7 Warehouse Autonomy Plan to Advance Self-Optimizing, Around-the-Clock Operation
-
Gamma Resources Announces Planned Radon Flux Baseline Survey at Mesa Arc Uranium Project in New Mexico, Provides Update on Project Timelines
-
China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption
-
Odyssey Behavioral Healthcare Launches Virtual Intensive Outpatient Mental Health Treatment for Adults
Exxel Pharma to Participate in a "New to Virtual Investor" Segment
Live moderated video webcast on Wednesday, February 5th at 4:00 PM ET
AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders, today announced that it will participate in a "New to Virtual Investor" segment on Wednesday, February 5, 2025 at 4:00 PM ET.
As part of the event, Soren Mogelsvang, PhD, President and Chief Executive Officer of Exxel Pharma, will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
A live video webcast will be available on the Investors page of the Company's website (exxelpharma.com). Viewers can also access the event on the Virtual Investor website at virtualinvestorco.com.
About Exxel Pharma
Exxel Pharma is a privately held pharmaceutical company focused on developing innovative therapeutics for neuronal hypersensitivity disorders. The Company's lead program, EX937, is a first-in-class, orally administered, proprietary small molecule designed to specifically and peripherally inhibit the fatty acid amide hydrolase (FAAH) enzyme. Exxel is initiating a first-in-human Phase 1/1b clinical study of EX937 for refractory chronic cough, a significant unmet medical need with no FDA-approved treatments. In preclinical studies, EX937 demonstrated robust efficacy in modulating chronic cough across multiple models. Furthermore, it has shown a favorable safety profile and is designed to avoid central side effects by being entirely excluded from the brain. EX937 also holds promise for a range of high-value indications, including hyperactive bladder, peripheral painful neuropathies, and migraine headaches. In addition to EX937, Exxel Pharma is advancing its ARN compounds, a second lead program targeting social anxiety disorder and autism spectrum disorder.
Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
E: [email protected]
SOURCE: Exxel Pharma, Inc.
View the original press release on ACCESS Newswire
L.Mason--AMWN
